At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Pravastatin in the Subjects With Prediabetes or Early Diabetes
In Brief
A Phase 4 clinical trial evaluating Pravastatin, Placebo (for Pravastatin), and 1 other intervention for Diabetes Mellitus and Prediabetic State. Completed, enrolled 44 participants across 1 site.
Detailed Summary
An increased risk of incident diabetes with statin therapy have been reported in several studies. However, it is not recommended to limit the use of statin for this reason since the absolute risk increase was small, and the cardiovascular event rate reduction with statins overweighed the risk of new diabetes (Scatter N et al. Lancet, 2010). Moreover, each statin may have different effect on the development of incident diabetes. In the West of Scotland Coronary Prevention Study, pravastatin therapy reduced the hazard of becoming diabetic by 30%. Also, with pravastatin use, an increase in adiponectin level, which is related to the improvement in insulin sensitivity, has been reported. In this clinical trial, the investigators are aiming to evaluate the effect of pravastatin on insulin resistance, insulin secretion, glycemic control, and adiponectin level in participants with prediabetes or early diabetes by assigning them in a 24 weeks of pravastatin therapy group or in a placebo group.
Study Details
Timeline
Interventions
Pravastatin 40mg once daily for 24 weeks and nutritional education by a nutritionist
Pill manufactured to mimic pravastatin 40mg tablet once daily for 24 weeks and nutritional education by a nutritionist
Only nutritional education by a nutritionist